The CEO of a promising biotech company must decide the best way to respond to the macro-economic recession of late 2008. He had intended to pursue an belligerent agenda transferring the Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the market of the firm.
This involved expanding headcount and the firm's facilities and he planned to finance this by taking venture debt. Although clinical trial data is extremely encouraging, questions about raising the total environment and his next venture round has made him question the wisdom of this plan. This case provides the opportunity to explore the true price of venture debt and when it's used to reach the targets of all parties to students - venture capitalists, entrepreneurs, and enterprise lenders.
PUBLICATION DATE: December 08, 2009 PRODUCT #: 510C12-HCB-CHI
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
NASCAR: Every Second Counts – Helping Win from the Pits
Habitat for Humanity International in South Africa
Identifying, Mapping, and Monitoring the Impact of Hybrid Firms
Royal Bank of Canada: Transforming Managers (A)
Goats: The Green Alternative (C)
OdontoPrev
How Penn State Turned a Crisis Into a Disaster: An Interview With Crisis Management Pioneer Steven Fink
Leading in the Age of Super-Transparency
Note on Dynamic Optimization
The Allergan Board Under Fire (B)
